Allianz Asset Management GmbH grew its position in shares of AtriCure Inc. (NASDAQ:ATRC) by 18.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 183,647 shares of the medical device company’s stock after acquiring an additional 29,153 shares during the quarter. Allianz Asset Management GmbH owned 0.53% of AtriCure worth $4,108,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in ATRC. US Bancorp DE boosted its position in AtriCure by 152.1% during the 2nd quarter. US Bancorp DE now owns 4,202 shares of the medical device company’s stock worth $102,000 after acquiring an additional 2,535 shares during the last quarter. Sei Investments Co. raised its stake in shares of AtriCure by 75.5% during the 2nd quarter. Sei Investments Co. now owns 6,933 shares of the medical device company’s stock worth $168,000 after purchasing an additional 2,983 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in shares of AtriCure during the 3rd quarter worth approximately $205,000. Legal & General Group Plc raised its stake in shares of AtriCure by 3.8% during the 2nd quarter. Legal & General Group Plc now owns 8,528 shares of the medical device company’s stock worth $208,000 after purchasing an additional 312 shares in the last quarter. Finally, Tudor Investment Corp ET AL bought a new stake in shares of AtriCure during the 2nd quarter worth approximately $253,000. 86.17% of the stock is owned by hedge funds and other institutional investors.
Shares of AtriCure Inc. (NASDAQ:ATRC) opened at $18.31 on Friday. AtriCure Inc. has a 12 month low of $14.78 and a 12 month high of $25.18. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.28 and a quick ratio of 1.65.
ATRC has been the topic of a number of analyst reports. Zacks Investment Research cut AtriCure from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Canaccord Genuity reiterated a “buy” rating and set a $28.00 price objective on shares of AtriCure in a research note on Monday, October 9th. Needham & Company LLC dropped their price objective on AtriCure from $26.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, November 2nd. ValuEngine cut AtriCure from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. Finally, TheStreet cut AtriCure from a “c-” rating to a “d+” rating in a research note on Wednesday, November 29th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $24.67.
In other AtriCure news, CFO M. Andrew Wade sold 2,000 shares of the stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $18.41, for a total transaction of $36,820.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director B Kristine Johnson acquired 1,500 shares of the stock in a transaction on Wednesday, November 8th. The shares were purchased at an average price of $18.36 per share, for a total transaction of $27,540.00. Following the transaction, the director now directly owns 10,969 shares in the company, valued at $201,390.84. The disclosure for this purchase can be found here. 10.00% of the stock is owned by company insiders.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.